Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCV+ Donor to HCV- Recipient Transplant Safety Trial
NCT04017338Phase 3Unknown
- Start
- Aug 2018
- Primary completion
- Dec 2020
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of glecaprevir, pibrentasvir, ezetimibe in hepatitis C (HCV). Status: unknown.
02
Drugs
glecaprevirpibrentasvirezetimibe
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT04017338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04017338.